Product Composition Clause Samples

Product Composition. As between the Parties, subject to Sections 2.1.3 and 2.1.4 with respect to the LNP Technology and subject to the replacement mechanism under Section 3.6, the clearance mechanism under Section 3.4 and Section 3.5, the composition restrictions under Section 3.2, the adjustment mechanism under Section 3.3, and the limitations to GSK’s decision-making rights set forth in Section 7.5.2b(i), GSK shall have the right, in its sole discretion, to determine the composition of a Product, including [*****].
View SourceView Similar (3)
Product Composition. Before begin of supplies, Supplier shall ensure the product registration in IMDS – International Material Data Systems and disclose all necessary documentation about the product and its composition, including the following: (a) Product technical data sheet, (b) Product safety data sheet, (c) Documentation in accordance with REACH regulation (Registration, Evaluation, Authorization and restriction of Chemicals), (d) Documentation in accordance with CONFLICT MINERALS regulations. Supplier clearly demonstrate understanding of the requirements for reporting conflict mineral content to ▇▇▇▇-▇▇▇▇▇. Supplier should be 100 percent certain that do not have any 3TG (tin, tantalum, tungsten and gold) in its supply chain products. (e) Any other material specific documentation required by clients, including information related to any changes of the ingredients and material origins.
View Source
Product Composition. For the avoidance of doubt, GSK shall be solely responsible for (and shall have sole decision-making rights for) the composition of a GSK Product, including adding or changing Antigens or Antigen Variants, as well as the primary vaccine Antigen. For the avoidance of doubt, subject to clause 2.2.6,##################################################################################################################################################################
View Source
Product Composition. SUBSTANCE NAME: ß-FARNESENE CAS #: ▇▇▇▇▇-▇▇-▇ MOLECULAR FORMULA: C15H 24 SYNONYMS: 1,6,10-Dodecatriene, 7,11-dimethyl-3-methylene, (6E) (TSCA, PICCS, ASIA-PAC) 1,6,10-Dodecatriene, 7,11-dimethyl-3-methylene, (E) (DSL, AICS) (E)-7,11-Dimethyl-3-methylenedodeca-1,6,10-triene (EINECS) (E)-7,11-Dimethyl-3-methylene-1,6,10-dodecatriene (ECL) CHEMICAL FAMILY: Terpene hydrocarbons
View Source
Product Composition. Before begin of supplies, Supplier shall ensure the product registration in IMDS – International Material Data Systems and disclose all necessary documentation about the product and its composition, including the following: (a) Product technical data sheet, (b) Product safety data sheet, (c) Documentation in accordance with REACH regulation (Registration, Evaluation, Authorization and restriction of Chemicals), (d) The supplier knows ▇▇▇▇-▇▇▇▇▇'▇ requirements, namely, the obligation to report the existence of chemical substances that appear in the “list of substances subject to authorization” or in the “list of substances subject to restrictions”, or even if they have a classification and harmonized labeling. (e) Documentation in accordance with CONFLICT MINERALS regulations. Supplier clearly demonstrate understanding of the requirements for reporting conflict mineral content to ▇▇▇▇-▇▇▇▇▇. Supplier should be 100 percent certain that do not have any 3TG (tin, tantalum, tungsten and gold) in its supply chain products. (f) Any other material specific documentation required by clients, including information related to any changes of the ingredients and material origins.
View Source

Related to Product Composition

  • Product NYISO will provide Energy Resource Interconnection Service and Capacity Resource Interconnection Service to Developer at the Point of Interconnection.

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Board Composition Each Holder agrees to vote, or cause to be voted, all Shares owned by such Holder, or over which such Holder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that at each annual or special meeting of stockholders at which an election of directors is held or pursuant to any written consent of the stockholders, subject to Section 5, the following persons shall be elected to the Board: (a) As the Series A Director, one person designated from time to time by a majority of the holders of Series A Preferred Stock (the “Series A Designee”), for so long as 1,000,000 share of Series A Preferred Stock are outstanding, which number is subject to appropriate adjustment for any stock splits, stock dividends, combinations, recapitalizations and the like, which individual shall initially be ▇▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇; (b) As the Common Stock Director, one person designated from time to time by a majority of the holders of Common Stock (the “Common Stock Designees”), which individual shall initially be ▇▇▇▇ ▇▇▇▇▇▇▇▇▇; and (c) The Company’s Chief Executive Officer, who as of the date of this Agreement is ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇ M.D. (the “CEO Director”), provided that if for any reason the CEO Director shall cease to serve as the Chief Executive Officer of the Company, each of the Holders shall promptly vote their respective Shares (i) to remove the former Chief Executive Officer of the Company from the Board if such person has not resigned as a member of the Board; and (ii) to elect such person’s replacement as Chief Executive Officer of the Company as the new CEO Director. To the extent that any of clauses (a) through (c) above shall not be applicable, any member of the Board who would otherwise have been designated in accordance with the terms thereof shall instead be voted upon by all the Holders of the Company entitled to vote thereon in accordance with, and pursuant to, the Restated Certificate. For purposes of this Agreement, an individual, firm, corporation, partnership, association, limited liability company, trust or any other entity (collectively, a “Person”) shall be deemed an “Affiliate” of another Person who, directly or indirectly, controls, is controlled by or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or registered investment company now or hereafter existing that is controlled by one (1) or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person.